Pfizer Research Grant Request for Proposals Competitive Grant Program – Pfizer Internal Review Process AI-Enabled Models for Timely COVID-19 Treatment with Nirmatrelvir/Ritonavir: Eligibility & Drug-Drug Interaction Management
Pfizer funds research using AI to improve outpatient COVID-19 treatment with nirmatrelvir/ritonavir by enhancing eligibility assessment and drug-drug interaction management.
Funder: Pfizer Inc.
Due Dates: July 7, 2026 (Full application submission deadline)
Funding Amounts: Up to $500,000 USD per project (2 years max); total program budget approx. $1,000,000 USD
Summary: Supports research using AI to improve eligibility and drug-drug interaction management for timely outpatient COVID-19 treatment with nirmatrelvir/ritonavir.
Key Information: Only organizations in Australia, Canada, China, Germany, Greece, Japan, Korea, or Taiwan are eligible.
Description
This competitive grant program from Pfizer seeks research proposals focused on leveraging artificial intelligence (AI) and advanced clinical decision support systems to improve safe and timely outpatient access to nirmatrelvir/ritonavir (Paxlovid) for COVID-19. The aim is to address barriers to delivering therapy within the recommended time window by developing AI-enabled solutions for identifying patient eligibility based on current clinical guidelines and proactively managing clinically significant drug-drug interactions (DDIs). Projects should enable real-time, patient-specific antiviral recommendations, reduce inappropriate exclusions and treatment delays, and improve clinical outcomes by minimizing progression to severe disease. Proposals must specify target countries and care settings, and should include innovative tools for medication adjustment and monitoring that ensure patient safety and optimal antiviral use.
